AtaiBeckley (ATAI) Research & Development (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Research & Development came in at $17.4 million in Q1 2026, up 53.73% year-on-year from $11.3 million in Q1 2025, and up 53.73% quarter-over-quarter from $11.3 million in Q1 2025.
AtaiBeckley (ATAI) Research & Development (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Research & Development data on file, last reported at $14.7 million in Q3 2025.
- For the quarter ending Q3 2025, Research & Development rose 18.61% year-over-year to $14.7 million; the trailing twelve-month figure through Sep 2025 stood at $56.0 million (up 687.75% YoY), and the FY2024 full-year result was $55.5 million, up 2672.75% from the prior year.
- Research & Development rose to $17.4 million in Q1 2026 per ATAI's latest filing, from $11.3 million in the prior quarter.
- Across five years, Research & Development topped out at $17.4 million in Q1 2026 and bottomed at $11.3 million in Q1 2025.
- A 5-year average of $7.6 million and a median of $13.3 million in 2023 frame the typical range for Research & Development.
- Across the five-year window, Research & Development jumped 461.53% in 2021 and slumped 482.35% in 2022, its largest moves.
- Tracing ATAI's Research & Development over 5 years: stood at $13.0 million in 2021, then tumbled by 482.35% to -$49.6 million in 2022, then increased by 7.23% to -$46.0 million in 2023, then jumped by 141.14% to $18.9 million in 2024, then decreased by 22.5% to $14.7 million in 2025.
- Business Quant data shows ATAI's Research & Development at $14.7 million in Q3 2025, $11.1 million in Q2 2025, and $11.3 million in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | AtaiBeckley | 2.56 Bn | 2.56 Bn | - | 14.68 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.41 Mn |
| Sep 30, 2025 | 14.68 Mn |
| Jun 30, 2025 | 11.09 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Dec 31, 2024 | 18.94 Mn |
| Sep 30, 2024 | 12.38 Mn |
| Jun 30, 2024 | 12.61 Mn |
| Mar 31, 2024 | 11.53 Mn |
| Dec 31, 2023 | -46.05 Mn |
| Sep 30, 2023 | 13.29 Mn |
| Jun 30, 2023 | 15.48 Mn |
| Mar 31, 2023 | 19.28 Mn |
| Dec 31, 2022 | -49.64 Mn |
| Sep 30, 2022 | 19.03 Mn |
| Jun 30, 2022 | 17.95 Mn |
| Mar 31, 2022 | 15.46 Mn |
| Dec 31, 2021 | 12.98 Mn |
| Sep 30, 2021 | 13.36 Mn |
| Jun 30, 2021 | 16.03 Mn |